PolyU has entered into a formal collaboration with Axis Therapeutics (Axis) to foster cancer immunotherapy research and development, with the aim of improving cancer treatment for patients in Hong Kong. The establishment of the PolyU-Axis Therapeutics Joint Laboratory for Immunotherapy facilitates clinical trials of new T-cell receptor therapy using the newly established clinical Current Good Manufacturing Practice (cGMP) facility at PolyU, which is compliant with the GMP Guide for the Advanced Therapy Products (ATPs), and the development of at least 30 new targeting agents against novel T-cell targets in cancer immunotherapy.